MedTrace Logo

Terazosin And Metabolic Energetics in Parkinson's Disease

NCT07464028 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2026-03-16

No results posted yet for this study

Summary

This study investigates if Terazosin can improve metabolism in PD.

Conditions

  • Parkinson's Disease (PD)

Interventions

DRUG

Terazosin 5 MG

This drug increases glycolysis in Parkinson's disease.

DRUG

Placebo

Placebo control for Terazosin

Sponsors & Collaborators

  • Nandakumar Narayanan

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-07-01
Primary Completion
2030-07-01
Completion
2031-07-01
FDA Drug
Yes

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07464028 on ClinicalTrials.gov